[Edity Therapeutics in WebWire] Edity Therapeutics enters into a strategic collaboration with Dr. Reddy’s Laboratories to advance novel cell therapy approach using Edity’s proprietary delivery platform

Edity Therapeutics announced a strategic collaboration with Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) to create novel cell therapy medicines by applying Edity’s proprietary delivery platform.

Read more here.